Sublingual Misoprostol versus Intramuscular Oxytocin for Prevention of Postpartum Hemorrhage in Uganda: A Double-Blind Randomized Non-Inferiority Trial

PLoS Medicine

Volumn 11, Issue 11, 2014, Pages

  Atukunda, Esther C ^a   Siedner, Mark J ^b   Obua, Celestino ^c   Mugyenyi, Godfrey R ^a   Twagirumukiza, Marc ^d   Agaba, Amon G ^a  

^a MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MISOPROSTOL; OXYTOCIN; OXYTOCIC AGENT;

ADULT; ARTICLE; BLEEDING; BLOOD CELL COUNT; BLOOD TRANSFUSION; CONTROLLED STUDY; DEATH; DIARRHEA; DOUBLE BLIND PROCEDURE; EMERGENCY SURGERY; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; PAIN; POSTPARTUM HEMORRHAGE; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIAL; SHIVERING; UGANDA; COMPARATIVE STUDY; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; LABOR; MATERNAL MORTALITY; PREGNANCY; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LABOR, OBSTETRIC; MATERNAL MORTALITY; MISOPROSTOL; OXYTOCICS; OXYTOCIN; POSTPARTUM HEMORRHAGE; PREGNANCY; UGANDA;

EID: 84922383244     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001752     Document Type: Article

References (36)

1. World Health Organization, United Nations Children's Fund, United Nations Population Fund, World Bank (2012) Trends in maternal mortality: 1990–2010. WHO, UNICEF, UNFPA and The World Bank estimates. Geneva: World Health Organization.
2. United Nations Department of Economic and Social Affairs Population Division (2013) World population prospects: the 2012 revision. New York: United Nations Department of Economic and Social Affairs Population Division.
3. Uganda Ministry of Health (2010) Clinical guidelines for prevention and treatment of post partum haemorrhage using misoprostol. Kampala: Uganda Ministry of Health.
4. World Health Organization (2012) WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: World Health Organization.
5. Prata N, Bell S, Weidert K, (2013) Prevention of postpartum hemorrhage in low-resource settings: current perspectives. Int J Womens Health 5: 737–752 doi:10.2147/IJWH.S51661
6. Atukunda EC, Brhlikova P, Agaba AG, Pollock AM, (2013) Registration, procurement, distribution, and use of misoprostol in Uganda: an interview-based observational study. Lancet 382: 10.
7. Stanton CK, Newton S, Mullany LC, Cofie P, Tawiah Agyemang C, et al. (2013) Effect on postpartum hemorrhage of prophylactic oxytocin (10 IU) by injection by community health officers in Ghana: a community-based, cluster-randomized trial. PLoS Med 10: e1001524.
8. Tang OS, Gemzell-Danielsson K, Ho PC, (2007) misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 99 (Suppl 2) S160–S167.
9. Katzung GB (2010) Basic principles of pharmacology. In: Katzung GB, Masters SB, Trevor AJ, editors. Basic and clinical pharmacology, 12th edition. New York: McGraw-Hill Medical.
10. International Federation of Gynecology and Obstetrics (2012) Prevention of postpartum hemorrhage with misoprostol. Int J Gynaecol Obstet 119: 213–214 doi:10.1016/j.ijgo.2012.09.002
11. Tuncalp O, Hofmeyr GJ, Gulmezoglu AM, (2012) Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev 8: CD000494 doi:10.1002/14651858.CD000494.pub4
12. Chu CS, Brhlikova P, Pollock AM, (2012) Rethinking WHO guidance: review of evidence for misoprostol use in the prevention of postpartum haemorrhage. J R Soc Med 105: 336–347 doi:10.1258/jrsm.2012.120044
13. Derman RJ, Kodkany BS, Goudar SS, Geller SE, Naik VA, et al. (2006) Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial. Lancet 368: 1248–1253 doi:10.1016/S0140-6736(06)69522-6
14. Mobeen N, Durocher J, Zuberi N, Jahan N, Blum J, et al. (2011) Administration of misoprostol by trained traditional birth attendants to prevent postpartum haemorrhage in homebirths in Pakistan: a randomised placebo-controlled trial. BJOG 118: 353–361.
15. Gulmezoglu AM, Villar J, Ngoc NT, Piaggio G, Carroli G, et al. (2001) WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet 358: 689–695.
16. Baskett TF, Persad VL, Clough HJ, Young DC, (2007) Misoprostol versus oxytocin for the reduction of postpartum blood loss. Int J Gynaecol Obstet 97: 2–5 doi:10.1016/j.ijgo.2006.12.016
17. Vaid A, Dadhwal V, Mittal S, Deka D, Misra R, et al. (2009) A randomized controlled trial of prophylactic sublingual misoprostol versus intramuscular methyl-ergometrine versus intramuscular 15-methyl PGF2alpha in active management of third stage of labor. Arch Gynecol Obstet 280: 893–897.
18. Vimala N, Mittal S, Kumar S, (2006) Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. Int J Gynaecol Obstet 92: 106–110.
19. Vimala N, Mittal S, Kumar S, Dadhwal V, Mehta S, (2004) Sublingual misoprostol versus methlergometrine for active management of third stage of labor. Int J Gynaecol Obstet 87: 1–5.
20. Uganda Ministry of Health (2010) Uganda clinical guidelines: national guidelines on management of common conditions. Kampala: Uganda Ministry of Health.
21. Bellad MB, Tara D, Ganachari MS, Mallapur MD, Goudar SS, et al. (2012) Prevention of postpartum haemorrhage with sublingual misoprostol or oxytocin: a double-blind randomised controlled trial. BJOG 119: 975–982 doi:10.1111/j.1471-0528.2012.03341.x
22. Hoj L, Cardoso P, Nielsen BB, Hvidman L, Nielsen J, et al. (2005) Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trial. BMJ 331: 723 doi:10.1136/bmj.331.7519.723
23. Piaggio G, Elbourne D, Pockock SJ, Evans SJ, Altman DG, et al. (2012) Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 308: 2594–2604.
24. Westhoff G, Cotter AM, Tolosa JE, (2013) Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev 10: CD001808 doi:10.1002/14651858.CD001808.pub2
25. Nordstrom L, Fogelstam K, Fridman G, Larsson A, Rydhstroem H, (1997) Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. Br J Obstet Gynaecol 104: 781–786.
26. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, et al. (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134: 663–694.
27. Tewatia R, Rani S, Srivastav U, Makhija B, (2014) Sublingual misoprostol versus intravenous oxytocin in prevention of post-partum hemorrhage. Arch Gynecol Obstet 289: 739–742.
28. Chaudhuri P, Biswas J, Mandal A, (2012) Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in low-risk women. Int J Gynaecol Obstet 116: 138–142 doi:10.1016/j.ijgo.2011.09.016
29. Weeks A, (2012) Commentary on “prevention of postpartum haemorrhage with sublingual misoprostol or oxytocin: a double-blind, randomised controlled trial”. BJOG 119: 982–983.
30. Lam H, Tang OS, Lee CP, Ho PC, (2004) A pilot-randomized comparison of sublingual misoprostol with syntometrine on the blood loss in third stage of labor. Acta Obstet Gynecol Scand 83: 650.
31. Elati A, Weeks A, (2012) Risk of fever after misoprostol for the prevention of postpartum hemorrhage: a meta-analysis. Obstet Gynecol 120: 1140–1148.
32. Durocher J, Bynum J, Leon W, Barrera G, Winikoff B, (2010) High fever following postpartum administration of sublingual misoprostol. BJOG 117: 845–852 doi:10.1111/j.1471-0528.2010.02564.x
33. Amant F, (2001) The misoprostal third stage study: a randomised controlled comparison between orally administered misoprostol and standard management. A double-blind placebo controlled randomised trial of misoprostol and oxytocin in the management of the third stage labour. BJOG 108: 338.
34. Babinszki A, Kerenyi T, Torok O, Grazi V, Lapinski RH, et al. (1999) Perinatal outcome in grand and great-grand multiparity: effects of parity on obstetric risk factors. Am J Obstet Gynecol 181: 669–674.
35. Tsu VD, (1993) Postpartum haemorrhage in Zimbabwe: a risk factor analysis. Br J Obstet Gynaecol 100: 327–333.
36. Stones RW, Paterson CM, Saunders NJ, (1993) Risk factors for major obstetric haemorrhage. Eur J Obstet Gynecol Reprod Biol 48: 15–18.